Heme Today Videos
Advertisement
Dr. John Gansner and Dr. Martina H. Slingsby argue this new agent can provide benefit across all bleeding disorders.
Heme Today spoke with Ulrike Reiss, MD, and Andrew Davidoff, MD, of the trial's investigator team.
Gene therapy is reshaping sickle cell care, raising awareness and advancing treatments beyond the lab.
The study led by Paul George, MD, PhD, also highlights the importance of patient regimen adherence to secure these benefits.
Adrián Mosquera Orgueira, MD, PhD, spoke of his team's study into machine learning tools for improving risk stratification.
ASH Awards Commitee Chair Ivan Maillard, MD, PhD, and prior awardee Rinku Majumder, PhD, tell of the Grant's positive impact.
An expert panel's review finds SCT has often been misattributed as the direct cause of mortality in patients who have SCT.
Organization-level changes at hospitals and medical groups are needed to meaningfully address this longstanding issue.
ASH's efforts pertain to professional recruitment as well as to address unique medical issues in patient populations.
Juan Jose Rodriguez-Sevilla, MD, PhD, summarizes current clinical knowledge about inflammation within MDS pathobiology.
Clinicians seek alternatives to biopsy for clinically evaluating bone marrow mutations in cytopenic patients.
A cohort lifetime study from Hamda Khan, MA, and Jason Hodges, PhD, MA, follows patients from pediatric into adult SCD care.
A recent study brings insight regarding the best timing for this CAR-T therapy in patients with prior BCMA-directed therapy.
Dr. Theodore Wun and Dr. Olubusola Oluwole investigated the causes of rising stroke rates among pediatric and adult patients.
A study has assessed cryogenically preserved ovarian tissue samples from women with SCD for any effects from hydroxyurea.
Soo Park, MD, and Zoya Qureshy, MD, explore the mentor-mentee relationship factor in clinicians' professional development.
In patients who have undergone CAR-T therapy, mortality risk from infection persists longer than from CRS or ICANS.
Initial findings from a phase I study show the compound significantly reduces the need for phlebotomy in patients with PV.
MDS experts tell of the clinical factors they consider when selecting from the available agent options.
An MDS expert panel discusses findings from the trial's comparison of luspatercept with ESAs in this setting.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.